Esculin
CAS 531-75-9
Esculin (CAS 531-75-9) is a pharmaceutical compound with 2 bioactivity targets and 32 adverse event associations.
Compound Identity
Matched identifiers and naming fields for the pharmaceutical compound record.
Cross-Reference to Cosmetics
Same-CAS ingredient record found in the cosmetics vertical.
Bioactivity & Target Interactions
Target-level activity records with assay counts, activity type, and measured value where present.
| Target | Activity | Value | Assays | Organism |
|---|---|---|---|---|
| - | Potency | 19495.464705882354 nM | 17 | - |
| - | IC50 | 569984.2066666667 nM | 2 | - |
Frequently Asked Questions
Short answers generated only from the same visible source-linked rows on this page.
What is Esculin used for in pharmaceutical contexts?
Esculin (CAS 531-75-9) is rendered as a pharmaceutical compound from the matched source rows; no DailyMed product-name rows are present in this page query.
What are the known adverse events for Esculin?
Esculin has 32 DrugCentral/FAERS adverse event associations. Rendered reaction terms include Angina pectoris, Appetite disorder, Asthma, Chest discomfort, Chest pain. Signal rows are source-linked records and should not be read as incidence rates or causality conclusions.
Is Esculin also used in cosmetics?
Yes. The ingredients table has a same-CAS cosmetic profile for Esculin with EU status "permitted".
What clinical phase is Esculin in?
No phase 1-4 clinical development badge is rendered for Esculin because the matched compound identifier rows do not contain a max-phase value.